Relevance of the prostate-specific antigen (PSA) nanotest compared to the classical PSA test in the organized mass screening of prostate cancer

被引:2
|
作者
Azzouzi, Abdel-Rahmene
Larre, Stephane
Cormier, Luc
Roupret, Morgan
Valeri, Antoine
Mangin, Philippe
Berthon, Philippe
Villette, Jean-Marie
Fiet, Jean
Cussenot, Olivier
机构
[1] CHU Angers, Dept Urol, F-49933 Angers, France
[2] CeRePP, UPRES, UFR, Biomed St Peres, Paris, France
[3] CHU Nancy Brabois, Dept Urol, Vandoeuvre Les Nancy, France
[4] CHU Cavale Blanche, Brest, France
[5] UroGene, Evry, France
[6] Hop St Louis, Dept Hormonol, Paris, France
[7] Inst Univ France, Paris, France
关键词
PSA; mass screening; prostate cancer; population surveillance;
D O I
10.1111/j.1464-410X.2006.06701.x
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
OBJECTIVE: To assess the reliability of a new measurement of prostate-specific antigen (PSA) using a blotting-paper assay (nanotest) compared to the standard PSA immunoassay. SUBJECTS AND METHODS: The PSA level was measured in 205 men volunteers (median age 70 years, range 41-75) using a nanotest and a standard PSA immunoassay, collected at the same time; 30 mu L of capillary blood placed on to a blotting paper were collected for the nanotest and sent by mail to the same laboratory for the two assays. The results were compared statistically using the Spearman test, the intraclass correlation coefficient and the Bland-Altman test. RESULTS: The nanotest threshold for an abnormal PSA level was 78 pg/mL, which corresponded to a standard PSA value of 3 ng/mL, with a sensitivity of 100%. There was a significant correlation (r = 0.98, Spearman test; P < 0.001) between the nanotest and the standard PSA assay. The intraclass correlation coefficient was 0.87. The Bland-Altman test showed a good agreement between the nanotest and the standard PSA assay, but there was an increasing proportional difference with increasing PSA value. CONCLUSION: There was a very high correlation between the nanotest and the standard PSA assay, especially for standard PSA levels of < 5 ng/mL. Economic and clinical studies are indicated to confirm the utility of the nanotest in organized mass screening of prostate cancer.
引用
收藏
页码:762 / 764
页数:3
相关论文
共 50 条
  • [1] Relevance of PSA-Nanotest on capillary blood in organized mass screening of prostate cancer
    Azzouzi, R
    Cormier, L
    Valeri, A
    Fournier, G
    Mangin, P
    Berthon, P
    Cussenot, O
    [J]. JOURNAL OF UROLOGY, 2002, 167 (04): : 330 - 330
  • [2] Prostate cancer screening with prostate-specific antigen (PSA) test: a clinical practice guideline
    Tikkinen, Kari A. O.
    Dahm, Philipp
    Lytvyn, Lyubov
    Heen, Anja F.
    Vernooij, Robin W. M.
    Siemieniuk, Reed A. C.
    Wheeler, Russell
    Vaughan, Bill
    Fobuzi, Awah Cletus
    Blanker, Marco H.
    Junod, Noelle
    Sommer, Johanna
    Stirnemann, Jerome
    Yoshimura, Manabu
    Auer, Reto
    MacDonald, Helen
    Guyatt, Gordon
    Vandvik, Per Olav
    Agoritsas, Thomas
    [J]. BMJ-BRITISH MEDICAL JOURNAL, 2018, 362
  • [3] Prostate cancer and prostate-specific antigen (PSA) screening in AustriaProstatakarzinom und PSA-Screening in Österreich
    Christian Vutuc
    Eva S. Schernhammer
    Gerald Haidinger
    Thomas Waldhör
    [J]. Wiener klinische Wochenschrift, 2005, 117 : 457 - 461
  • [4] Prostate-Specific Antigen (PSA) Screening for Prostate Cancer Revisiting the Evidence
    Carter, H. Ballentine
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2018, 319 (18): : 1866 - 1868
  • [5] Inappropriate prostate-specific antigen (PSA) screening
    不详
    [J]. NEW ZEALAND MEDICAL JOURNAL, 2007, 120 (1266) : 133 - 134
  • [6] PROSTATE-SPECIFIC ANTIGEN (PSA)
    HOWANITZ, JH
    [J]. DISEASE MARKERS, 1993, 11 (01) : 3 - 10
  • [7] Prostate cancer screening with prostate-specific antigen (PSA) test: a systematic review and meta-analysis
    Ilic, Dragan
    Djulbegovic, Mia
    Jung, Jae Hung
    Hwang, Eu Chang
    Zhou, Qi
    Cleves, Anne
    Agoritsas, Thomas
    Dahm, Philipp
    [J]. BMJ-BRITISH MEDICAL JOURNAL, 2018, 362
  • [8] Prostate-specific antigen (PSA) velocity: a test of controversial benefit in the era of increased prostate cancer screening
    Borofsky, Michael S.
    Makarov, Danil V.
    [J]. ASIAN JOURNAL OF ANDROLOGY, 2011, 13 (04) : 614 - 615
  • [9] PROSTATE-SPECIFIC ANTIGEN (PSA) IN PROSTATE DISEASE
    PEYRET, C
    LEROY, M
    TEILLAC, P
    RABAUD, B
    NAJEAN, Y
    LEDUC, A
    [J]. JOURNAL DE BIOPHYSIQUE ET DE BIOMECANIQUE, 1987, 11 (03): : 125 - 125
  • [10] Update on prostate-specific antigen (PSA)-based screening
    Suzuki, Hiroyoshi
    [J]. INTERNATIONAL JOURNAL OF UROLOGY, 2009, 16 (09) : 711 - 711